|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.440 USD | +2.95% |
|
+5.17% | +35.56% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| P/E (N) | Price to Book (N) | PEG (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 12.51x | - | -0.04x | - | - | - | - | 197M | ||
| 34.92x | 21.06x | 0.72x | 12.63x | 25.81x | 26.64x | 0.57% | 1,060B | ||
| 27.42x | 6.9x | -1.82x | 6.3x | 17.1x | 18.91x | 2.08% | 619B | ||
| 30x | 1336.57x | 0.12x | 7.34x | 15.02x | 15.46x | 2.76% | 438B | ||
| 17.98x | 6.66x | 1.08x | 4.45x | 11.01x | 12.36x | 2.97% | 333B | ||
| 21.52x | 6.42x | -29.87x | 5.52x | 13.36x | 14.61x | 2.86% | 282B | ||
| 21.56x | 5.04x | 0.97x | 4.53x | 12.65x | 13.53x | 1.94% | 267B | ||
| 14.17x | 6.24x | -11.4x | 5.3x | 10.9x | 12.75x | 3.52% | 218B | ||
| 23.77x | 18.24x | 3.2x | 6.31x | 11.12x | 14.44x | 2.78% | 196B | ||
| -46.02x | 8.12x | 0.33x | 5.6x | 31.12x | 61.83x | 2.5% | 161B | ||
| 12.29x | 1.57x | 0.28x | 3.03x | 7.56x | 8.66x | 7.14% | 138B | ||
| 27.87x | 5.6x | 2.04x | 8.39x | 18.94x | 19.79x | -.--% | 123B | ||
| 11.32x | 5.05x | 0.24x | 3.1x | 8.26x | 8.99x | 4.37% | 118B | ||
| 11.5x | 1.22x | 3.25x | 2.15x | 6.91x | 7.87x | 5.58% | 105B | ||
| 12.42x | 4.52x | 1.04x | 2.76x | 8.06x | 9.13x | 3.55% | 105B | ||
| 23.91x | 5.42x | 1.39x | 8.1x | 15.33x | 16.03x | 1.85% | 75.29B | ||
| 21.12x | 1.75x | -0.13x | 1.78x | 8.42x | 14x | 0.47% | 56.29B | ||
| 39.74x | 5.38x | 2.11x | 9x | 29.95x | 30.85x | 0.48% | 54.27B | ||
| 43.57x | 1.15x | 53.26x | 2.67x | 9.81x | 27.17x | 3.81% | 52.42B | ||
| 18.68x | 1.88x | 3.99x | 3.4x | 12.78x | 14.34x | 2.21% | 42.8B | ||
| Average | 19.01x | 76.25x | 1.54x | 5.39x | 14.43x | 18.28x | 2.71% | 222.16B | |
| Weighted average by Cap. | 23.06x | 141.14x | -1.35x | 7.17x | 16.91x | 19.43x | 2.27% |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
















